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The use of electrical stimulation (ES) should be considered for treating nonhealing pressure ulcers (PUs), but optimal ES
wound treatment protocols have yet to be established. A randomized, controlled, double-blind clinical study was conducted to evaluate the effects of cathodal and anodal high-voltage monophasic pulsed current (HVMPC) on periwound
skin blood flow (PSBF) and size reduction of Stage 2 to Stage 4 PUs of at least 4 weeks’ duration. Persons >18 years of
age, hospitalized with neurological injuries, at high risk for PU development (Norton scale <14 points; Waterlow scale >15
points), and with at least 1 Stage 2 to Stage 4 PU were eligible to participate in the study. Persons with necrotic wounds,
osteomyelitis, electronic or metal implants in the PU area, PUs in need of surgical intervention, acute wound inflammation, diabetes (HBA1c >7%), diabetic neuropathy, cancer, and/or allergies to standard wound treatments were excluded.
Patients were randomly assigned to 1 of 3 groups: anodal (AG), cathodal (CG), or placebo (PG) ES. All groups received individualized PU prevention and standard wound care. In the PG, sham ES was applied; the AG and CG were treated with
anodal and cathodal HVMPC, respectively (154 μs 100 Hz; 360 µC/second; 1.08 C/day), 50 minutes per day, 5 days per
week, for a maximum of 8 weeks. PSBF was measured using laser Doppler flowmetry at baseline, week 2, and week 4,
and wound surface area measurements were obtained and analyzed using a digitizer connected to a personal computer.
Data analysis utilized the maximum-likelihood chi-squared test, the analysis of variance Kruskal-Wallis test, the KruskalWallis post-hoc test, and Spearman’s rank order correlation. Nonlinear approximation based on exponential function was
used to calculate treatment time needed to reduce the wound area by 50%. In all tests, the level of significance was set
at P ≤.05. Of the 61 participating patients, 20 were in the AG (mean age 53.2 ± 13.82 years), 21 in the CG (mean age 55.67
± 17.83 years), and 20 in the PG (mean age 52.5 ± 13.18 years). PUs (baseline size range 1.01 cm2 to 59.57 cm2; duration 4
to 48 weeks) were most frequently located in the sacral region (73.77%) and classified as Stage 3 (62.29%). PSBF at week
2 was significantly higher in the AG and CG than in the PG (P <.05). Week 4 differences were not statistically significant.
Wound percentage area reduction calculated at week 8 for the AG (64.10% ± 29.22%) and CG (74.06% ± 23.23%) were
significantly different from PG ulcers (41.42% ± 27.88%; P = .0391 and P = .0024, respectively). In both ES groups, PSBF
at week 4 and percent wound surface area reductions between weeks 4 and 8 were positively correlated, but only the AG
correlation was statistically significant (P = .049). In this study, both ES modalities improved blood flow and wound area
reduction rate. Studies examining optimal ES treatment times for healing to occur, the effect of comorbidities and baseline wound variables on ES outcomes, and the nature of the relationship between blood flow and healing are necessary.
Keywords: randomized controlled trial, pressure ulcer, wound healing, electrical stimulation, skin blood flow
Index: Ostomy Wound Management 2018;64(2):10–29

doi: 10.25270/owm.2018.2.1029

Potential Conflicts of Interest: The study was funded by the Academy of Physical Education, Katowice, Poland.

10

OSTOMY WOUND MANAGEMENT® FEBRUARY 2018

www.o-wm.com

EFFECTS OF ELECTRICAL STIMULATION

Ostomy Wound Management 2018;64(2):10–29

AT

E

Key Points
• A randomized, controlled clinical study was conducted
to examine the effect of 2 types of electrical stimulation
(ES) — cathodal and anodal high-voltage monophasic
pulsed current — on periwound skin blood flow and size
reduction of Stage 2 to Stage 4 pressure ulcers (PUs) as
compared to control (sham) stimulation.
• Sixty-one (61) patients with neurological impairment
(61 ulcers) received 1 of the 3 interventions 50 minutes
per day, 5 days per week, for a maximum of 8 weeks.
• The majority of patients had a Stage 3 PU in the sacral
area for the previous 10 to 13 weeks.
• At week 2, blood flow was significantly higher in both
ES groups than in the control group, and wound area
reduction was significantly greater after 8 weeks.
• Studies to examine optimal ES treatment times for PU
healing to occur and to increase understanding about the
relationship between blood flow and healing are needed.
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linical practice guidelines1,2 suggest electrical stimulation (ES) should be considered for treating recalcitrant
Stage 2, Stage 3, and Stage 4 pressure ulcers (PUs). The recommendation is based on A-level strength of evidence from
controlled trials on PUs in humans.1
ES influence on blood flow. A common factor that may
prevent or delay wound healing is compromised perfusion
of the wound and periwound tissues. In a preclinical, experimental study with 10 healthy volunteers (age 20 to 40 years),
Petrofsky et al3 investigated whether skin blood flow changes
induced by ES could be attributed to the electrical current
effect on nitric oxide (NO) that is known to dilate blood vessels. From the first part of the study,3 the authors concluded
a 4-minute application of biphasic sine current in the thigh
area significantly increased skin blood flow compared to its
pre-ES level (P <.01). In the second part of the study, biphasic
sine current and iontophoresis with a NO synthetase inhibitor (N-nitro-L-arginine methyl-ester) were applied simultaneously to the same part of the body in the same patients.
A significant reduction in skin blood flow (P <.01) was observed. The authors concluded the increase in skin blood flow
in the first part of the experiment was caused by the release of
NO induced by ES.
A randomized, double-blind, controlled, placebo clinical
study by Mohajeri-Tehrani et al4 (N = 20) investigated the
effect of low-intensity direct current on the release of plasma vascular endothelial growth factor (VEGF) and NO in
patients with diabetic foot ulcerations. After 12 ES sessions,
a significantly higher level of NO was noted in blood plasma
in the ES-treated patients compared to patients in the control (placebo) ES group (P = .04). A randomized, singleblind, controlled clinical trial by Asadi et al5 showed ES significantly increased wound-fluid levels of hypoxic inducible
factor-1α and VEGF while decreasing wound surface area
after 12 sessions of ES with low-intensity direct current applied at sensory level. In vitro studies by Zhao et al6 and Bai
et al7 have shown that an electric field (75 to 200 mV/mm)
induced by a direct current, comparable in amplitude to the
measurable current of injury at a wound, caused a direct
release of VEGF by vascular endothelial cells6 and induced
directional migration, orientation, and elongation of endothelial cells, vascular fibroblasts, and smooth muscle cells.7 It
also was shown that vascular endothelial cells migrate toward
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the cathode, as opposed to vascular fibroblasts and smooth
muscle cells that migrate toward the anode.
The cited preclinical3,6,7 and clinical4,5 studies have demonstrated that direct4-7 and biphasic pulsed3 currents increase
the release of NO, dilating blood vessels,3,4 stimulating the release of angiogenetic factors (VEGF4-6 and of hypoxic inducible factor-1α5), and induce reorientation, elongation, and
migration of endothelial cells as well as vascular fibroblasts
and smooth muscle cells,7 all of which exert a positive influence on wound healing.
Clinical evidence supporting the use of high-voltage
monophasic pulsed current (HVMPC) for wound treatment. Chronic wounds treated with ES utilize subsensory
amplitudes of direct and pulsed currents with amperage
below 1 mA (so-called microcurrents)8,9 as well as sensory
stimulation below the muscle contraction threshold. Sensory
ES involves the application of HVMPC10-18 and low-voltage
monophasic19-21 and biphasic22-24 pulsed currents. The authors of critical and systematic reviews published in 201425
and 201726 concluded both high-voltage and low-voltage
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criterion was stated in the ANZCTR registration form. However, because the number of qualifying patients in the rehabilitation center turned out to be insufficient for statistical
analysis, patients with brain injuries from a cerebral stroke
or skull trauma also were included. These changes were reported to the ANZCTR. Patients who could not receive ES
(ie, persons with cancer, electronic implants, metal implants,
osteomyelitis in the PU area, tunneling, necrotic wounds, and
PUs requiring surgical intervention), patients with acute inflammation in the wound area, and patients with conditions
impeding wound healing such as diabetes (HbA1c >7%),
critical wound infection, allergies to standard wound treatment, and/or alcoholism were excluded from the study.
Randomization. Patients were informed in writing by the
research manager about the aim and course of the study and
that they could withdraw from the study at any time without
having to state a reason and without any consequences for
their further treatment. Patients who consented to participate in the trial (or whose legal guardians gave consent for
their inclusion) were randomly assigned to 3 groups.
The study was initially designed to involve 3 groups of
15 people. Accordingly, a person independent of the trial
was given 3 sets of 15 slips of paper that were marked with
letters A, B, and C denoting group assignment: A for the
SWC + anodal HVMPC group, B for the SWC + cathodal
HVMPC group, and C for the SWC + sham ES group. The
person, who was not aware of what the letters meant, inserted the slips into 45 computer-generated, randomly drawn
envelopes. Once sealed, the envelopes were delivered to the
main investigator in charge of allocating patients to groups.
Before the trial commenced, the envelopes were opened 1 at
a time in the presence of a physiotherapist and the patient
concerned was directed to the appropriate group. Because
more persons volunteered to participate in the study than
originally planned, 3 additional sets of 6 envelopes were
prepared for each group and the randomization of patients
proceeded as described. The final sample consisted of 61
patients. The increased number of participants diminished
the risk of study bias.
Blinding. All patients, medical personnel, and researchers were blinded as to what type of ES was being applied to
individual patients (anodal ES, cathodal ES, or sham ES).
The exceptions were the main investigator and the principal
physiotherapist who set the equipment to apply active or
sham ES. The person responsible for statistical analysis also
was blinded.
Study variables. Demographic information on the patients enrolled in the study was obtained from standardized
participant interviews, physical examinations, the results of
additional examinations, and the history of concomitant
diseases. Study variables for assessing wounds, PU risk, and
patients’ nutritional status were collected with paper-pencil
instruments and transferred to a data sheet. Other data, such
as patient case history, blood cell count results, and previous
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pulsed currents can produce consistently positive results in
patients with chronic wounds.
Several clinical studies compared HVMPC to standard
wound care (SWC) alone12,15,16 or SWC + sham ES10,11,13,17,18
to treat PUs,10,11,15-18 venous leg ulcers,12,14 and diabetic foot
ulcers.13 The main results and methodology of HVMPC
in PU treatment studies are summarized in Table 1. The
outcomes of the cited studies10,11,15-18 indicated PU area
decreased more in the SWC + ES groups than in controls
treated with HVMPC.
In reviews of clinical27,28 and epidemiological studies,29
wound closure was the crucial endpoint in evaluating treatment efficacy. However, clinical studies utilizing ES rarely
last long enough for closure to be achieved. Only 1 study10
involved treatment of PUs with HVMPC until full closure.
In trials that terminated before wounds were closed, the percentage wound area reduction from baseline at weeks 4, 6,
or 12 of treatment was a crucial indicator of treatment efficacy.11-18 The time during which PU surface area decreases
from baseline by at least 50% is also important.27-29
Three (3) clinical studies evaluated changes in wound surface area (WSA) and periwound skin blood flow (PSBF) in
ulcers that received 2 and 4 weeks of ES with sensory level
low-voltage, biphasic, pulsed currents.22-24 To address a gap in
the research literature, this clinical study was designed assess
the effect of cathodal and anodal high-voltage HVMPC on
PSBF and WSA reduction in Stage 2 to Stage 4 PUs in adult
persons with neurological injuries.
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Methods
Study design. This prospective, randomized, blind, controlled, clinical trial was designed to compare PSBF around
the PU area after 2 and 4 weeks of treatment as well as WSA
reduction during 8 weeks of treatment between 3 groups of
patients receiving SWC plus cathodal ES, anodal ES, or sham
ES, respectively. Parallel treatment of patients in all 3 groups
and equal numbers of patients in the groups were assumed.
Ethical approval. Ethical approval was granted by the
Academy Bioethics Commission.
The trial was prospectively registered with the AustralianNew Zealand Clinical Trials Registry (ANZCTR): ANZCTRN
12615001281583.
Study enrollment and criteria. Patients screened for the
study were treated as inpatients at 1 rehabilitation center between December 1, 2015, and January, 30, 2017. Their eligibility
to participate was assessed by their physician using the following criteria: neurological injuries (spinal cord injury, ischemic
stroke, and/or blunt trauma to the head); age 18 years or older;
high risk of PU development (<14 points on the Norton scale
and >15 points on the Waterlow scale); and Stage 2, Stage 3, or
Stage 4 PU of at least 0.5 cm2 in size and at least 4 weeks’ duration located on the pelvic girdle or lower extremities.
Because it was initially planned that only patients with spinal cord injuries would be enrolled in the trial, this inclusion
12
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Table 1. Summary of controlled clinical high-voltage monophasic pulsed current (HVMPC) studiesa in patients
with pressure ulcers (PUs)
Kloth and
Feedar10
(1988)

Griffin et al11
(1991)

Houghton et
al15 (2010)

Franek et
al16 (2012)

Polak et al17
(2016)

Polak et al18 (2017)

Total number of
patients

16

17

34

50

49

63

Number of patients (ES group)

9

8

16

26

25

CESG=23/C+AESG=20

SWC+CES/SWC+C+AES

Treatment
ES group

SWC+ES

SWC+ES

SWC+ES

SWC+ES

SWC+sham ES

SWC

SWC

SWC+sham ES

70.1

32.5

50.3

59

ES groups:
Mean patient age
(years)

2–4

2–4

2–3

4.08

2.34

3.48

4.54

Mean duration
of PU

Not reported

4.5 weeks

1.2 years

Treatment

On PU

On PU

On PU

Reference

30cm from PU

Distally from PU

U

Polarity of treatment electrode

Anode
(reversed if
healing progress was not
observed)

Cathode

Pulse duration/
frequency

100 μs/105 pps

Electric charge

79.92

HVMPC methods:
Positioning of
electrodes:

2–4 in both ES groups

CES = 9.59/C+AES = 7.37

2.54 months

CES 2.41 mo/C+AES
2.65mo.

On PU

On PU

On PU

At least
20cm from
PU

At least 20cm
from PU

At least 20cm from PU

Cathode
1-2 weeks,
then anode

Cathode

CESG – cathode
C+AESG – cathode for first
week, than anode

50 μs / 100 pps
for first 20 min;
10 pps for next
20 min

100 μs/100
pps

154 μs/100 pps

154 μs/100 pps

D

At least 20cm
from PU

Initially cathode, then reversed weekly

T

O

Not reported
/100 pps

CESG = 79.35/C+AESG
79.65

2–3

PL

3.17 months

SWC+sham ES

10.58

IC

4

Mean baseline
WSA (cm2)

N

Stage of PU

E

SWC+ES
SWC+sham ES

AT

Control group

342 μC/s

500 μC/s

Not reported

Not
reported

250 μC/s

250 μC/s

45 minutes

60 minutes

40 minutes

50 minutes

50 minutes

50 minutes

Frequency of ES

1 a day/5 a
week

1 a day/7 a week

8 a day/7 a
week

1 a day/5 a
week

1 a day/5 a week

1 a day/5 a week

Total time of ES
per week

3.75 hours

7 hours

37 hours

4.16 hours

4.16 hours

4.16 hours

Period of treatment

7.3 weeks

20 successive
days

12 weeks

6 weeks

6 weeks

6 weeks

100% PUs
closed

WSA i 80%

WSA i 70%
Closed:
A: 100 %
Stage 2 PUs;
B: 33.3%
Stage 3-4 PUs

WSA i
88.9%

A: WSA i 88.31
% closed:
B: 45% Stage
2 PUs
C: 17.65% Stage
3 PUs

A: CESG – WSA i 82.34%
A: C+AESG – WSA i 70.77
% closed;
B: 47.8% PUs in CESG
B: 45% in C+AESG

D

O

Duration of ES

Main outcomes:
ES group (ESG)

(continued)
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Table 1. Summary of controlled clinical high-voltage monophasic pulsed current (HVMPC) studiesa in patients
with pressure ulcers (PUs)
Griffin et al11
(1991)

Houghton et
al15 (2010)

Franek et
al16 (2012)

Polak et al17
(2016)

Polak et al18 (2017)

Control group
(CG)

WSA i 28.9%
over a mean
period of 7.4
weeks

WSA i 52%

WSA i 36%
Closed:
A: 100% Stage
2 PUs;
B: 7.1% Stage
3-4 PUs

WSA i 44.4
%

A: WSA i 54.65
% Closed: B:
35.29% Stage
2 PUs C: 6.25%
Stage 3 PUs

WSA i 40.53%
Closed:
B: 0% PUs

Level of significance (P)

Not reported

P (ESG:CG)=.05

A: P (ESG:CG)
=.048
B: P (ESG:CG)
=.62
C: P (ESG:CG)
=.55

P (ESG:CG)

A: P (ESG:CG)
=.046
B: P (ESG:CG)
=.74
C: P (ESG:CG)
=.60

A: P (CESG:CG)=.0006; A:
P (C+AESG:CG) =.0124; A:
P (CESG:C+AESG)=.9932;
B: P (CESG:CG) = .013;
B: P (C+AESG:CG) = .045;
B: P (CESG:C+AESG)=.48

AT

=.00003

E

Kloth and
Feedar10
(1988)

anemia, thyroid dysfunction, impaired glycemic control, dehydration, protein deficit, hypoalbuminemia, vitamin level,
indicators of inflammation (C-reactive protein), and nitrogen balance.34,35 Diet was reviewed to assess intake of
healthy and nonhealthy nutrients and fluid losses. Nutritional status was quantified by means of the Nutritional
Risk Score (2002).36
Anemia. Anemia was diagnosed as hemoglobin level <13.4
g/dL in men and <12 g/dL in women. In cases where mean
corpuscular volume (MCV) erythrocyte was <80 fl, blood
iron concentration was determined. When MCV erythrocyte
was above 100 fl, blood B12 concentration was tested.
Interventions. All patients in the cathodal ES, anodal ES,
and placebo groups received SWC (prevention measures,
wound care, and physical treatment) under the supervision
of the physician and the principle investigator following best
practices.1,2,37 Each patient was assessed by an interdisciplinary team consisting of a physician, a nurse, a physiotherapist,
and a dietitian.
Individualization. The team developed individual wound
prevention and treatment programs in consideration of patients’ needs regarding PU prevention and nutritional intervention, the optimization of the wound dressing protocol,
and incontinence management. To protect the trial participants from developing more PUs, pressure-redistribution
surfaces, foam devices, and pillows were used. Patients who
were immobile were repositioned by a nurse or physiotherapist at least every 2 hours, and persons who could move
were instructed to change position as often as they could.
Malnourished patients received individual nutritional support. They were assisted during meals by a nurse or a medical assistant who made sure the quantity and quality of food
and liquids they ingested followed the dietitian’s guidelines.
Nutritional supplementation with proteins, vitamins, and
minerals was administered when necessary. Patients who did
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treatment results, were obtained from the electronic hospital
database. The information then was entered to a computer
database enabling data analysis.
Wound assessment. Before treatment, patients’ wounds
were examined by a physician. Patients with PUs covered
with eschar and with wounds showing signs of acute inflammation were excluded from the study. Patients with a PU covered with slough or with PUs in the granulation and epithelialization phases were included in the study. Wound depth was
determined by a physician based on the criteria developed by
the National Pressure Ulcer Advisory Panel1 (Stage 2 PUs =
partial-thickness loss of the dermis presenting as a shallow
open ulcer with a red pink wound bed, no slough; Stage 3
PUs = full-thickness tissue loss and subcutaneous fat possibly
visible but not the bone, tendon, or muscles; and Stage 4 PU
= full-thickness tissue loss, muscle/bone exposed).
PU risk. Patients’ risk of PU development was assessed
with the Norton scale30 and the Waterlow scale31 with respect
to factors such as patient gender and age, body composition
and weight, mobility, concomitant diseases (primarily central
nervous system injuries, diabetes, anemia), history of smoking, appetite and level of nourishment, and medications used
(mainly anti-inflammatory drugs, cytostatics, and steroids).
Nutritional status. In assessing patients’ nutritional status, malnutrition was defined as a state resulting from lack of
intake or uptake of nutrition that leads to altered body composition (decreased fat free mass) and body cell mass leading
to diminished physical and mental function and impaired
clinical outcome from disease.32 The primary diagnostic criteria of malnutrition included body mass index (BMI) <18.5
kg/m2 as indicated by the underweight definition created by
the World Health Organization or combined weight loss and
reduced BMI.33
To determine patients’ nutritional status, their blood
samples also were tested for markers of metabolic disorders,

IC

a
double-peaked impulses; amperage at sensory level
ES=electrical stimulation; PU=pressure ulcers; SWC=standard wound care; WSA=wound surface area; ESG=electrical stimulation group; CG=control group;
CESG=cathodal ES group; C+AESG=cathodal + anodal ES group; mo=months; no=number
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Cathodal ES group (CG). HVMPC protocol in the CG
was almost the same as the AG protocol; the only difference
was cathodal (not anodal) stimulation was used. The protocol of HVMPC in both ES groups was based on methods used
in earlier clinical trials using anodal10 and cathodal11,14,17,18 ES
in patients with PUs10,11,17,18 and venous leg ulcers.14
Placebo ES group (PG). This group received SWC and
sham ES. The arrangement of electrodes during the procedure was the same as in the ES groups. The monitor of the ES
unit displayed all parameters, but because the electrodes were
connected to the inactive electrical circuit current energy was
not delivered to wounds.
The main physiotherapist connected the electrodes and
selected the polarity of the treatment electrode. The procedure was performed in an inconspicuous manner so neither
the patient nor the members of the medical team could see
whether real or sham ES was applied. In the active ES groups,
voltage was set above 100 V (the same value was displayed
on the monitor for patients receiving sham ES), which did
not cause muscle contractions, only weak tactile sensations.
Because most patients in the groups had tactile sensory impairments and did not feel the current, patients in the sham
ES group did not know they were not receiving treatment.
All treatment sessions had the same duration and frequency
(50-minute sessions, once a day, 5 times a week) and followed
the same protocol whether sham or active ES was applied.
The electrodes were sterilized before and after each session in an approved disinfectant solution (Incidin Liquid and
Sani-Cloth Active, Ecolab). As soon as the procedure ended,
patients’ wounds were thoroughly washed with a 0.9% sodium chloride solution and covered with SWC dressings as
described earlier.
The trial design assumed wounds would be monitored for
8 weeks in all groups, representing the average length of stay
in the facility. Patients hospitalized longer than 8 weeks were
to be treated and monitored for wound healing as before. In
patients with more than 1 PU, all wounds were treated, but
only the deepest PU (the most advanced stage) was included
in the study analysis.
Measures/data collection.
PSBF. PSBF was measured using a laser Doppler imager
(PERIFLUX 5000, Perimed, Järfälla, Sweden) linked to a personal computer with the PeriSoft software for Windows (version 25.5; Galen Ortopedia Sp z o.o., PL, Bierun, Poland) that
also was used for making computations and storing the results. A single point, infrared (IR), laser blood flow probe was
used; it was calibrated before each measurement. To ensure
the stability of readings, the laser was warmed for 15 minutes
before measurement commenced. The probe was attached to
the skin using a small piece of adhesive tape. Over the 4 weeks
of treatment, 3 blood flow tests were conducted: before the
first treatment session, at week 2 (after 10 ES procedures),
and at week 4 (after 20 ES procedures). All measurements
were conducted in the patient’s room, usually in an ambient

D

O

N

O

T

D

U

PL

not consume sufficient amounts of food received enteral or
parental nutrition.1
Wound care protocol. Wounds were regularly assessed by
the physician throughout the period of the study with a view
to selecting topical treatments to appropriately address moisture control, bacterial burden, and debridement needs. When
wound infection was suspected, a swab was taken to identify
the bacteria and prepare an antibiogram.
Before ES was applied, necrotic tissue was removed
from PUs with surgical/sharp, conservative sharp, or enzymatic debridement.
A moist wound environment was maintained consistently
with hydrogel, hydrocolloid, or alginate dressings. Dressing
type depended on the PU stage, phase of healing, the amount
of wound secretion, and pain severity. Wounds covered
with slough and granulating wounds were covered between
ES procedures with alginate dressings (high or moderate
exudate levels; surface and deep wounds) and hydrocolloid
dressings (moderate or low exudate levels; surface wounds).
Granulating and epithelializing wounds with minimal exudate were covered between ES procedures with hydrocolloid
or hydrogel dressings.
Infected wounds were washed with antiseptics that included Octenilin Wound Gel (Schülke, Norderstedt, Germany); Octenisept solution (Schülke); and/or Actolind W
Solution/Gel (Polvet Healthcare Teodorowski SJ, Laziska,
Gorne, Poland). PUs also were washed with Kodan Tinktur
forte solution (Schülke) and Skinsept (Ecolab, Monheim am
Rhein, Germany). According to the information provided by
the manufacturers of these antiseptic agents, none of them is
cytotoxic to healthy cells.
Patients with elevated leukocyte levels received antibiotics
selected according to the results of microbiological culture
and sensitivity tests. All immobile patients received low-molecular-weight heparin.
Anodal ES group (AG). Patients in the AG were administered SWC and anodal HVMPC energy. The device used
to deliver HVMPC was the Intelect Advanced Combo unit,
Model 2771 (Chattanooga Group, Vista, CA) with 2 independent electrical circuits, of which only 1 was active. The
device generated a twin-peak monophasic pulse (154 µs)
consisting of 2 77-µs exponential pulses in rapid succession.
Pulse frequency was set at 100 pps and voltage above 100 V
for amperage of 0.36 A that did not elicit motor reactions.
The electrodes delivered a 360 µC per second charge (1.08
C per day). Patients participated in 5 50-minute, once-aday sessions held weekdays (Monday through Friday). All
patients had a personal set of conductive carbon-rubber
electrodes. During the procedure, the treatment electrode
(5.0 cm x 10.0 cm) was placed on the wound and the return electrode (10.0 cm x 10.0 cm) was attached to healthy
periwound skin at least 20 cm from the PU. Both electrodes
were separated from the tissue by aseptic gauze pads saturated with physiological saline.
16
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Table 2. Wound outcome calculations
Formula

Abbreviation/description

Equation 1

Percentage change in PSBF
at week 2 from baseline (%)

PSBF2-0 = (PSBF2 – PSBF0) x
100%/PSBF0

PSBF2-0 – Percentage change in
PSBF at week 2 from baseline (%)
PSBF2 – PSBF at week 2 [perfusion
units] PSBF0 – PSBF at baseline
(perfusion units)

Equation 2

Percentage change in PSBF
at week 4 from baseline (%)

PSBF4-0 = (PSBF4 – PSBF0) x
100%/PSBF0

PSBF4-0 – Percentage change in
PSBF at week 4 from baseline (%)
PSBF4 – PSBF at week 4 (perfusion
units) PSBF0 – PSBF at baseline
(perfusion units)

Equation 3

Relative WSA at a given
week of treatment (cm2)

WSArel(t) = WSA (t)/WSA (t=0)

WSArel(t) - relative WSA (cm2])WSA
(t) – WSA at given week’s end (cm2)
WSA (t=0) – baseline WSA (cm2)

Equation 4

Nonlinear approximation
-t/T1/2
exponential function used to WSArel(t) = WSA = 2
calculate T½

Equation 5

Percentage WSA reduction
at week 8 (%)

PAR 8 = (WSA 0 – WSA 8) x 100%/
WSA 0

PAR 8 - percentage WSA reduction
at week 8 (%) WSA 0 – initial WSA
(cm2) WSA 8 – WSA at week 8 (cm2)

Equation 6

Percentage WSA reduction
at week 2 (%)

PAR 2 = (WSA 0 – WSA 2) x 100%/
WSA 0

PAR 2 - percentage WSA reduction
at week 2 (%) WSA 0 – initial WSA
(cm2) WSA 2 – WSA at week 2 (cm2)

Equation 7

Percentage WSA reduction
at week 4 from week 2 (%)

PAR 2-4 = (WSA 2 – WSA 4) x
100%/WSA 2

Equation 8

Percentage WSA reduction
at week 8 from week 4 (%)
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WSArel(t) - relative WSA area (cm2) t
– week of treatment T½ – approximate time that WSA would need to
decrease by half.

O

T

PAR 4-8 = (WSA 4 – WSA 8) x
100%/WSA 4

PAR 2-4 percentage WSA reduction
at week 4 from week 2 (%) WSA 2 –
WSA at week 2 (cm2) WSA 4 – WSA
at week 4 (cm2)
PAR 4-8 percentage WSA reduction
at week 8 from week 4 (%) WSA 4 –
WSA at week 4 (cm2) WSA 8 – WSA
at week 8 (cm2)

PSBF=periwound skin blood flow; WSA= wound surface area

D

O

N

temperature of 21˚ C to 22˚ C. Patients could assume a position that was comfortable for them (supine or sidelying). In
preparation for the measurement of skin blood flow, the skin
around the wound first was washed with aseptic fluid. Using
the patient’s head as the 12 o’clock reference point, the laser
probe was attached to wound edges at 4 points (superior, inferior, right, and left side of the wound). At each point, blood
flow was measured for 20 seconds. The temperature under
the probe was maintained at all times at a constant level of
33˚ C. The authors of other clinical trials used a similar protocol to measure skin blood flow.38
Wound measurements. Wound (cm2) measurements
were taken and area calculated at baseline and after each week
of therapy. If a PU closed before week 8 ended, the day it
closed was recorded. The WSA was determined by tracing the
wound shape onto acetate sheets and from the sheets onto
rigid, transparent film for measurement with a planimeter.
Measurements were processed by a digitizer (Mutoh Kurta
XGT; ALTEK Information Technology Inc, (Spokane, WA)
18
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connected to a personal computer with the C-GEO software
(version 4.0; Nadowski SoftLine, PL, Tychy, Poland) that
also was used for making computations and storing the results. Measurement errors caused by irregular wound shapes
ranged from 2.7% (for PUs of 70 cm2 in size) to 37.9% (PUs
<1 cm2). The method used to estimate wound size has been
presented in an earlier study.16
Primary outcome. The primary outcome of the trial was
PSBF at weeks 2 and 4 of treatment and between-group differences in the flow. To compare the study groups, percentage
changes in PSBF at weeks 2 (PSBF 2-0) and 4 (PSBF 4-0) were
calculated using equations 1 and 2 described in Table 2.
Secondary outcomes. The secondary outcome was the
rate of change in wound area. It was estimated as the nonlinear approximation of the time during which PU area would
decrease from baseline by 50% (T½). First, the nonlinear
approximation of the relative wound area in each week of
treatment (WSArel[t]) was calculated to ensure the comparability of WSA change rates regardless of treatment length
www.o-wm.com
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Patient characteristics were tested for normal distribution
using the Shapiro-Wilk W-test, which showed their distribution was not normal. The Levene test revealed heterogeneity of variance. Despite the absence of normal distribution
and because of low absolute values of skewness and kurtosis
(<2.5), a mean was used as the central value and standard
deviation as a measure of dispersion.
The homogeneity of patients’ characteristics between
groups was assessed using the maximum-likelihood chisquared test, the analysis of variance (ANOVA) Kruskal-Wallis test, and the Kruskal-Wallis post-hoc test.
To compare test and control groups’ mean PSBF2, PSBF4,
and PAR8, the ANOVA Kruskal-Wallis test and the KruskalWallis post-hoc test were employed. The nonlinear approximation was calculated using the exponential function (equation 4, see Table 2).
PSBF and PAR were tested for correlation with Spearman’s rank order correlation.
The following correlations were calculated between:
1) skin blood flow at baseline (PSBF0) and the percentage change in wound surface area noted at week
2 of treatment (PAR 2; equation 6 in Table 2);
2) skin blood flow at week 2 (PSBF2) and a change in
wound surface area from week 2 to week 4 (PAR 2-4;
equation 7 in Table 2); and
3) skin blood flow at week 4 (PSBF4) and change in
wound surface area from week 4 to week 8 (PAR 4-8;
Equation 8 in Table 2).

D

O

N

O

T

D

U

PL

(see equation 3 in Table 2). For the sake of illustration, the
relative wound area of 20 cm2 at week 0 (baseline) was calculated as WSArel(0) = WSA (0)/WSA (t=0) = 20 cm2/20 cm2 =
1. For a wound area of 15 cm2 at week 1, the relative area is
given by WSArel(1) = WSA (1)/WSA (t=0) = 15 cm2/20 cm2 =
0.75 cm2. In the next step, the nonlinear approximation was
performed using the exponential model presented as equation 4 in Table 2. Percentage wound area reduction at week 2
and 8 also was calculated (see Table 2). Finally, the number of
PUs closed during the 8-week study and duration of time to
closure for ulcers that healed were analyzed, and correlations
between PSBF and changes in wound area were examined.
Statistical analysis. All statistical analyses were performed
by a person blinded to the ES devices using Statistica software
(version 13.0, StatSoft Polska Sp. z o.o, Krakow, Poland). In
all tests, the level of significance was P ≤.05.
Group sizes for the trial were determined through a pilot
of this study during which 3 groups of 4 patients with PUs
were treated with AG, CG, and PG. At week 2, percentage
changes in PSBF from baseline were calculated and compared
between pairs of groups: AG and PG and CG and PG. The
greatest standard deviation of PSBF2 calculated for the groups
(92.38%) and the smallest between-group difference for PSBF2
(75.00%) indicated that statistically significant between-group
differences (at P <.05) in PSBF2 could be obtained with groups
of at least 12 participants. Taking advantage of the fact that
the number of patients willing to participate in the study was
greater than originally planned, enrollment continued and the
final sample was enlarged to 61 patients to reduce the risk of
error if some of them dropped out before the end of treatment.
Because PSBF values obtained at the end of treatment
were considerably different from those calculated with the
pilot study data, the relative values of PSBF were subjected
to statistical analysis to minimize the risk of baseline interpatient differences biasing the results of the main study. Relative
values also were used to estimate changes in WSA at week 8
(PAR8) and the amount of time necessary for WSA to decrease by half (WSArel[t]) (nonlinear approximation) and to
calculate correlations between PSBF and percentage reductions in wound area between weeks 0 and 2 (PAR 0-2), 2 and
4 (PAR 2-4), and 4 and 8 (PAR 4-8).
To retain data of all randomly allocated participants, an
intent-to-treat analysis was performed. Data that were not
available were approximated using an exponential regression
function written as WSA = b exp(-at), where WSA is wound
surface area; b and a are respectively, the regression constant
and the exponential regression coefficient calculated for each
patient using WSA (cm2) obtained over the period of treatment; exp is the exponential regression function with a base
of e ≈ 2.718282 (the Euler’s number); and t is the week of
treatment. The function allows WSA decreases39 to be described and can be calculated with data from at least 3 weeks.
The exponential correlation coefficient proved negative for
each patient and higher than 0.9 for the absolute WSA.
www.o-wm.com

Results
Of the 73 persons screened for the trial, 12 failed to meet
the inclusion criteria. The other 61 persons were randomly
assigned to groups AG (20), CG (21) and PG (20). Between 4
and 8 weeks of treatment, 19 individuals (31.15%) dropped
out from the trial. A statistical analysis was applied to all data
obtained, including data from patients who dropped out between weeks 4 and 8. The flow of participants through the
trial is illustrated in Figure 1.
Baseline patient and wound characteristics.
Sample characteristics. Of the 61 patients enrolled in the
trial, 27 were women (44.26%) and 34 were men (55.74%),
age range 22–78 years. The risk of PU development, assessed
with the Norton and Waterlow scales, was <14 points and
>15 points, respectively, for all patients; 10 patients (16.39%)
were obese (BMI >30) and 16 (26.23%) were considerably
underweight (BMI <18.5); 45 patients (73.77%) were immobile and needed assistance to change positions; 23 (37.70%)
smoked cigarettes before they became ill; and 35 (57.38%)
were malnourished and administered nutrition therapy.
Twenty-seven (27) patients (44.26%) had spinal cord injury, 32 (52.46%) had experienced a cerebral stroke, and 3
(4.92%) had a head injury. Tetra- or quadriplegia was diagnosed in 21 (34.43%) patients, 19 (31.15%) had paraplegia,
and 20 (32.79%) had hemiparesis. Nineteen (19) patients
FEBRUARY 2018 OSTOMY WOUND MANAGEMENT®
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Figure 1. Flow diagram of the study.
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(31.15%) had type 2 diabetes and 26 (42.62%) had anemia. The 61 PUs treated as part of the protocol ranged in
size from 1.01 cm2 to 59.57 cm2; 9 were Stage 2 (14.75%),
38 were Stage 3 (62.29%), and 14 were Stage 4 (22.95%).
Most PUs were located in the sacral region (45; 73.77%); 7
(11.45%) were located on the ischial tuberosity or the trochanter and 9 (14.75%) on the lower extremities (lower leg
and foot). Forty (40; 65.57%) patients had more than 1 PU.
The duration of the study PUs varied from 4 to 48 weeks. At
baseline, most PUs (41; 67.21%) had started to granulate, 16
(26.23%) wounds were covered with slough, and in 4 wounds
(6.56%) reepithelialization occurred. Between ES treatments,
hydrogel dressings were applied in 38 (62.3%) patients, hydrocolloid dressings in 16 (26.2%) patients, and alginate in
7 (11.5%) patients. PSBF measured at baseline ranged from
9.33 to 86.08 perfusion units, and blood flow in healthy skin
approximately 20 cm to 30 cm from the wound edges was 4.3
to 34.92 perfusion units.
According to the baseline demographic and wound characteristics of the patients (see Table 3), the groups were not
significantly different for any of the characteristics considered (P >.05).
Anodal ES group characteristics. The AG included 20
patients (8 women, 12 men, average age 53.2 ± 13.82 years).
Mean PU risk on the Norton and Waterlow Scales was 10
20
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± 2.63 and 31.3 ± 6.96, respectively. Two (2; 10%) patients
were obese (BMI >30), 6 (30%) were underweight (BMI
<18.5), 15 (75%) were immobile and needed assistance to
change position, 8 (40%) smoked cigarettes, and 11 (55%)
were malnourished and were administered nutrition therapy.
Nine (9) patients (45%) had spinal cord injury, 10 (50%) had
experienced a cerebral stroke, and 1 (5%) had a head injury.
Six (6; 30%) patients had tetra- or quadriplegia, 7 (35%)
had paraplegia, and 6 (30%) had hemiparesis. Five (5) patients (25%) had type 2 diabetes and 9 (45%) had anemia.
The patients had a total of 20 PUs, mean size 17.88 ± 16.68
cm2: 2 PUs were Stage 2 (10%), 13 Stage 3 (65%), and 5 Stage
4 (25%). Most PUs were located in the sacral region (15;
75%), 2 (10%) were located on the ischial tuberosity or the
trochanter, and 3 (15%) on the lower extremities (lower leg
and foot). The mean duration of the PUs was 13.9 ± 11.21
weeks. Twelve (12; 60%) patients had more than 1 PU. At
baseline, most PUs (13; 65%) started to granulate, 6 (30%)
were covered with slough, and reepithelialization occurred in
1 wound (5%). Between ES treatments, hydrogel dressings
were applied in 13 (65%) patients, hydrocolloid dressings in
4 (20%), and alginate in 3 (15%). The mean PSBF was 46.42
± 20.42 perfusion units, and blood flow in healthy skin approximately 20 cm to 30 cm from the edges of the wound was
12.53 ± 7.13 perfusion units.
www.o-wm.com
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Table 3. Baseline patient and pressure ulcer characteristics (N=61)
Variable

Anode ES group

Sample size (n)
b

a

a

21

20

11 (52.38%)/10 (47.62%)

8 (40%)/12 (60%)

Mean (SD)

53.20 (13.82)

55.67 (17.83)

52.50 (13.18)

Median/Lower - upper quartile

53.5/47-61

55/53-70

53/49-61

BMI >30;

2 (10%)

6 (28.57%)

2 (10%)

BMI <18.5

6 (30%)

5 (23.81%)

Mean (SD)

10 (2.63)

9.72 (2.31)

10.05 (1.96)

Median/Lower–upper quartile

10/8-12

10/8-12

10/8.5-12

Mean (SD)

31.3 (6.96)

30.5 (6.83)

31.8 (8.13)

Median / Lower - upper quartile

30/27-37

30.5/25-34

32.5/25-37.5

Age [years]:

Norton scale (points)

Waterlow scale (points)

Etiology of neurological injury (n, %):

E

Body mass index (BMI) (n, %):
5 (25%)

AT

a
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a

Placebo ES group

8 (40%)/12 (60%)

Gender (n): Female/Male

PL

a

Cathode ES group

Spinal cord injury

9 (45%)

8 (38.10%)

10 (50%)

Cerebral stroke

10 (50%)

13 (61.90%)

9 (45%)

Head injury

1 (5%)

1 (4.76%)

1 (5%)

Tetra/Quadriplegia (n, %)

6 (30%)

6 (28.57%)

9 (45%)

Paraplegia (n, %)

7 (35%)

7 (33.33%)

5 (25%)

a

Hemiparesis (n, %)

6 (30%)

8 (38.10%)

6 (30%)

a

Concomitant diseases (n, %)

5 (25%)

8 (38.10%)

6 (30%)

D

a

U

a

Diabetes (HbA1c <7%)

9 (45%)

11 (52.38%)

6 (30%)

11 (55%)

11 (52.38%)

13 (65%)

17.88 (16.68)

19.25 (16.47)

25.12 (17.42)

10.68 /4.76-22.08

14.31 5.05-26.35

21.66/9.66-42.38

Mean (SD)

46.42 (20.42)

37.37 (21.50)

45.61 (15.73)

Median/Lower–upper quartile

49/37.68-56

30.85/15.66-60.67

44.81/34.22-55.89

Mean (SD)

12.53 (7.13)

12.07 (7.52)

13.76 (4.54)

Median/Lower - upper quartile

10.64/8.01-14.41

10.26/6.23-17.15

13.82 / 10.23-16.36

Mean (SD)

13.90 (11.21)

11.62 (8.98)

10.85 (8.59)

Median /Lower–upper quartile

9/8–13

8/8-12

8/6-12

Stage 2

2 (10%)

4 (19.05%)

3 (15%)

Stage 3

13 (65%)

12 (57.14%)

13 (65%)

Stage 4

5 (25%)

5 (23.81%)

4 (20%)

T

Anemia
Malnourished (n, %)

a,b

WSA of PUs (cm2)

Mean (SD)

O

b,c

N

Median / Lower–upper quartile
b,c

Skin blood flow (perfusion unit)

O

In the ulcer area

D

In healthy skin 30 cm from PU

b,c

a

Duration of PUs (weeks):

PU depth/stage (NPUAP staging, n, %)
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Table 3. Baseline patient and pressure ulcer characteristics (N=61)
Variable

a

Anode ES group

Cathode ES group

Placebo ES group

Sacrum

15 (75%)

16 (76.19%)

14 (70%)

Ischial tuberosity or trochanter major

2 (10%)

2 (9.52%)

3 (15%)

Lower leg or foot

3 (15%)

3 (14.29%)

3 (15%)

Location (n, %)

PU characteristic/stage of healing (n, %)
Slough present

6 (30%)

4 (19.05%)

6 (30%)

Granulating

13 (65%)

16 (76.20%)

12 (60%)

Reepithelializing

1 (5%)

1 (4.76%)

E

a

2 (10%)

chi-squared
b
ANOVA Kruskall-Wallis Test
c
post-hoc Kruskal-Wallis Test
In all tests, the between-group differences were not statistically significant (P >.05)
SD=standard deviation; ES=electrical stimulation; WSA=wound surface area; PU=pressure ulcer;NPUAP=National Pressure Ulcer Advisory Panel

to change position, 9 (45%) smoked cigarettes, and 14 (70%)
were malnourished and were administered nutrition therapy.
Ten (10) patients (50%) had spinal cord injury, 9 (45%) had
experienced a cerebral stroke, and 1 (5%) had a head injury.
Nine (9; 45%) patients had tetra- or quadriplegia, 5 (25%)
had paraplegia, and 6 (30%) had hemiparesis. Six (6) patients
(30%) had type 2 diabetes and 6 (30%) had anemia.
The mean size of the 20 PUs was 25.12 ± 17.42 cm2; 3 were
Stage 2 (15%), 13 Stage 3 (65%), and 4 Stage 4 (20%). Most
were located in the sacral region (14; 70%), 3 (15%) on the
ischial tuberosity or the trochanter, and 3 (15%) were on the
lower extremities (lower leg and foot). The mean duration
of the PUs was 10.85 ± 8.59 weeks; 14 patients (70%) had
more than 1 PU. At baseline, more than half of the PUs in the
study (12; 60%) started to granulate, 6 (30%) were covered
with slough, and in 2 PUs (10%) reepithelialization occurred.
Between ES treatments, 14 patients (70%) received hydrogel
dressings, 5 (25%) received hydrocolloid dressings, and 1
(5%) received alginate. Mean PSBF was 45.61 ± 15.73 perfusion units, and blood flow in healthy skin approximately 20
cm to 30 cm from the edges of the wound was 13.76 ± 4.54
perfusion units.
Primary outcome. The cumulative change in PSBF flow
after 2 weeks of treatment (PSBF2) was 109.52% (95% confidence interval [CI]: 44.59-174.45) for the AG, 131.54% (95%
CI: 60.28-202.80) for the CG, and 35.83% (95% CI: 14.6357.02) for the PG (see Table 4). The CIs of the mean PSBF2
values overlapped between AG:PG and CG:PG, but the mean
PSBF2 calculated for the PG was smaller than the smallest
CIs for the AG and the CG, showing that the results obtained
for AG and CG groups were statistically more significant than
those obtained for the PG. These results were supported by
the ANOVA Kruskal-Wallis and post-hoc Kruskal-Wallis
tests. The ANOVA Kruskal-Wallis test showed changes in
PBSF were significantly different among the 3 groups (AG,
CG, PG; P = .0129). The post-hoc Kruskal-Wallis test showed
statistically significant differences between the AG and PG
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Cathodal ES group characteristics. The CG included
21 patients (11 women, 10 men, average age 55.67 ± 17.83
years). The mean PU risk per the Norton and Waterlow Scales
was 9.72 ± 2.31 and 30.5 ± 6.83, respectively. Six (6) patients
(28.57%) were obese (BMI >30) and 5 (23.81%) were underweight (BMI <18.5). Eighteen (18) patients (85.71%)
were immobile and needed assistance to change position,
6 (28.57%) smoked cigarettes, and 11 (52.38%) were malnourished and were administered nutrition therapy. Eight
(8) patients (38.10%) had spinal cord injury, 13 (61.90%)
had experienced a cerebral stroke, and 1 (4.76%) had a head
injury. Six (6) patients (28.57%) had tetra- or quadriplegia,
7 (33.33%) had paraplegia, and 8 (38.10%) were diagnosed
with hemiparesis. Eight (8) patients (38.10%) had type 2 diabetes and 11 (52.38%) had anemia.
The average size of the 21 PUs was 19.25 ± 16.47 cm2;
4 were Stage 2 (19.05%), 12 were Stage 3 (57.14%), and 5
were Stage 4 (23.81%). At baseline, most PUs were located
in the sacral region (16; 76.19%), 2 (9.52%) were on the
ischial tuberosity or the trochanter and 3 (14.29%) on the
lower extremities (lower leg and foot). The mean duration
of the PUs was 11.62 ± 8.98 weeks; 14 patients (66.67%) had
more than 1 PU. Most PUs (16; 76.19%) started to granulate,
4 (19.05%) wounds were covered with slough, and in 1 PU
(4.76%) reepithelialization occurred. Between ES treatments,
hydrogel dressings were applied in 11 (52.38%) patients, hydrocolloid dressings in 7 (33.33%) patients, and alginate in 3
(14.29%) patients. The mean PSBF was 37.37 ± 21.50 perfusion units, and blood flow in healthy skin approximately 20
cm to 30 cm from the edges of the wound was 12.07 ± 7.52
perfusion units.
Placebo ES group characteristics. The PG included 20 patients (8 women and 12 men, average age 52.50 ± 13.18 years).
Mean PU risk as per the Norton and Waterlow Scales was
10.05 ± 1.96 and 31.8 ± 8.13, respectively. Two (2, 10%) patients were obese (BMI >30) and 5 (25%) were underweight
(BMI <18.5); 13 (65%) were immobile and needed assistance
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Table 4. Periwound skin blood flow (N=61)
Group

Periwound skin blood flow

Percentage change in periwound skin
blood flow

At week 2

At week 4

[%]

Between baseline
and week 4

Anode ES group/AG
N=20

46.42 (20.42)
27.59–47.16

79.82 (27.37)
67.01–92.63

64.66 (23.83)
53.51–75.81

109.52 (138.73)
44.59 – 174.45

89.30 (144.25)
21.79–156.81

Cathode ES group/
CG N=21

37.37 (21.50)
27.58–47.16

68.30 (30.75)
54.31–82.30

51.33 (27.83)
38.66–63.95

131.54 (156.55)
60.28 – 202.80

88.25 (153.90)
18.19–158.30

Placebo group/PG
N=20

45.61 (15.73)
38.24–52.97

59.77 (25.58)
47.80–71.75

56.54 (16.62)
48.76–64.32

35.83 (45.29)
14.63 – 57.02

34.53 (44.08)
13.90–55.16

Level of significance

P(AG:CG:PG)=.0129;
P(AG vs CG)=.9999;
b
P(AG vs PG)=.0470;
b
P(CG vs PG)=.0152;

b

IC

ANOVA Kruskal-Wallis Test. b post-hoc Kruskal-Wallis Test; ES=electrical stimulation

a
P(AG:CG:PG)=74
P(AG vs CG)=.9999;
b
P(AG vs PG)=.9999;
b
P(CG vs PG)=.9999

AT

a

b

Group

T1/2

PL

Table 5. Nonlinear exponential approximation of time necessary for wound area to decrease by half from
baseline (N=61)
Confidence interval
+95%

AG

4.30

0.202

0.262

Cathode ES group

CG

3.86

0.233

0.284

Placebo group

PG

9.86

0.087

O

N

O

T

D

0.116

Figure 2. Nonlinear exponential approximation of the
length of time necessary for wound area to decrease by
half from baseline (dots correspond to observed mean
values of relative wound surface area; whiskers represent 95% confidence interval). The length of treatment
necessary for wound surface area to decrease from
baseline by half (T1/2) was 4.30 weeks in the anodal
group (AG), 3.86 weeks in the cathodal ES group (CG),
and 9.86 weeks in the sham group (PG). The analysis of
confidence intervals for T1/2 showed that the lengths
were significantly different between the AG and PG (P
<.05) and between the CG and PG (P <.05).
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[Perfusion unit]

P(AG vs PG)≤.05

P(CG vs PG)≤.05

groups (P = .0470) and CG and PG groups (P = .0152). The
AG and CG were not found to be significantly different from
each other (P = .9999) (see Table 4).
The cumulative change in PSBF after 4 weeks of treatment (PSBF4) was 89.30% (95% CI: 21.79-156.81) for the
AG, 88.25% (95% CI: 18.19-158.30) for the CG, and 34.53%
(95% CI: 13.90-55.16) for the PG. Differences among AG,
CG, and PG were not statistically significant: the ANOVA
Kruskal-Wallis test showed P = .74, and the post-hoc Kruskal-Wallis tests showed that in AG versus CG P = .9999; in
AG versus PG P = .9999; and in CG versus PG P = .9999 (see
Table 4).
Secondary outcomes. The nonlinear approximation of
treatment results showed that to decrease WSA from baseline
by half (T½) would require 4.30 weeks of treatment (95%
CI: 0.20-0.26) in the AG, 3.86 (95% CI: 0.23-0.28) in the CG,
and 9.86 (95% CI: 0.09-0.12) in the PG. The analysis of CIs
for T½ showed that the periods were statistically significant
different between the AG and the PG and between the CG
and the PG (P <.05) but not between the AG and the CG (see
Table 5 and Figure 2).
The cumulative percentage area reduction after 8 weeks
of treatment (PAR8) was 64.10% (95% CI: 50.42-77.78)
for the AG, 74.06% (95% CI: 63.48-84.63) for the CG, and
41.42% (95% CI: 28.37-54.47) for the PG. The PAR8 for
CG was significantly higher statistically than that obtained
FEBRUARY 2018 OSTOMY WOUND MANAGEMENT®
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Table 6. Pressure ulcer size (n=61)

Over 8 weeks of treatment, 4
of the 20 (20%) PUs in the AG, 7
of 21 (33%) in the CG, and 2 of
20 (10%) in the PG closed. DifPercentage area
ferences among the groups were
reduction (%)
not statistically significant: for
At week 8
AG versus PG, P = .3721; for CG
64.10 (29.22)
versus PG, P = .0645; and for AG
50.42– 77.78
versus CG, P =.3331. Average du74.06 (23.23)
ration of treatment to wound clo63.48–84.63
sure was 6.7 weeks (95% CI: 5.0441.42 (27.88)
8.36) in the AG, 7.38 weeks (95%
28.37 – 54.47
CI: 5.72-9.04) in the CG, and 6.05
a
P(AG:CG:PG)=.0026; weeks (95% CI: 4.92-7.18) in the
b
P(AG vs. CG)=.9999; PG. Differences among the groups
b
P(AG vs. PG)=.0391; (AG:CG:PG) were not statistically
b
P(CG vs. PG)=.0024
significant (P = .5111).
In the AG, PSBF at baseline
(PSBF0) was negatively correlated
with percentage wound area reduction after 2 weeks of treatment (PAR 0-2; P = .0361), meaning that greater baseline
PSBF was associated with smaller reduction in wound area
over the first 2 weeks of therapy. A positive correlation between PSBF at week 2 (PSBF2) and week 4 (PSBF4) and percentage wound area reduction between weeks 2 and 4 (PAR
2-4), as well as between weeks 4–8 (PAR 4-8), was indicative
of a positive relationship between greater PSBF and a smaller
reduction in wound area. In the AG, positive correlation between PSBF4 and PAR 4 to 8 was statistically significant (P =
.049; see Table 7). In the CG, positive correlation (although
not statistically significant [P = .161]) was established between PSBF at week 4 and PAR 4–8. For PG, no positive correlations between blood flow at weeks 2 and 4 and PAR 2–4
and PAR 4–8 were determined (see Table 7).
No adverse effects of applying HVMPC were observed in
this study.

Before treatment

At week 8

Anode ES group/AG
N=20

17.88 (18.68)
9.13–26.62

8.32 (11.76)
2.82–13.82

Cathode ES group/
CG N=21

19.25 (16.47)
11.76–26.75

6.46 (8.97)
2.37–10.54

Placebo group/PG
N=20

25.12 (17.42)
16.96–33.27

16.38 (13.90)
9.88–22.89

Level of significance

ANOVA Kruskal-Wallis Test; bpost-hoc Kruskal-Wallis Test

Table 7. Correlationsa between periwound skin
blood flow (PSBF) and percent wound area
reduction (PAR) (N=61)
Variables

N

R

P

PSBF at week 0: PAR 2 (%)

20

-0.433

.036

PSBF at week 2: PAR2–4 (%)

20

0.122

PSBF at week 4: PAR 4–8 (%)

20

0.389

21

PSBF at week 2: PAR 2-4 (%)

0.103

.656

21

-0.064

.784

21

0.318

.161

O

PSBF at week 4: PAR 4–8 (%)

.049

T

PSBF at week 0: PAR 2 (%)

.608

D

Cathode ES group

U

Anode ES group

PL

a

Placebo ES group (control)

20

0.064

.788

PSBF at week 2: PAR 2–4 (%)

20

-0.139

.557

PSBF at week 4: PAR 4–8 (%)

20

-0.120

.612

N

PSBF at week 0: PAR 2 (%)

Spearman’s rank correlation; N=number; R=correlation coefficient; P
=level of significance
PAR 2 percentage wound area reduction at week 2 in relation to baseline; PAR 2–4 percentage wound area reduction at week 4 in relation to
week 2;PAR 4–8 percentage wound area reduction at week 8 in relation
to week 4

D

O

a

for the PG, as indicated by nonoverlapping CIs of the mean
PAR8 values and results of the post-hoc Kruskal-Wallis test
(P = .0024). The CIs for the mean PAR8 values overlapped
between AG:PG, but the mean PAR8 for PG was smaller than
the smallest confidence intervals for AG, meaning that results
obtained for the AG were also statistically more significant
than those obtained for the PG. The finding was supported
by the post-hoc Kruskal-Wallis test (P = .0391). No statistically significant differences were noted between the AG and
the CG (P = .9999) (see Table 6).
24

AT

Wound surface area
(cm2)

IC

Group

E

Mean (SD)
95% Confidence interval

OSTOMY WOUND MANAGEMENT® FEBRUARY 2018

Discussion
Statement and principal findings. The trial has shown
that in patients with neurological injuries an 8-week treatment program consisting of SWC plus anodal HVMPC
and/or SWC plus cathodal HVMPC can increase PSBF
and reduce PU surface area more significantly than SWC
alone. PUs treated with SWC plus anodal and cathodal ES
decreased in size by half, significantly faster than when only
SWC was provided.
In this trial, increases in PSBF measured at weeks 2 and
4 of treatment were not significantly different between
groups receiving anodal and cathodal ES, nor was percentage wound area reduction significantly different between
groups after 8 weeks of treatment. This implies anodal and
cathodal HVMPC have a similar effect on PSBF and PU area
reduction. In both groups receiving HVMPC, the amount of
blood flow in wound edges and WSA decrease were positively
www.o-wm.com
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correlated with each other. In the group treated with anodal HVMPC, a positive
correlation between the amount of blood flow after 2 weeks of treatment and WSA
decrease between weeks 2 and 4 was observed. In both ES groups, the amount of
blood flow at week 4 of treatment positively correlated with WSA decrease between
weeks 4 and 8. In the anodal ES group, the correlation was statistically significant.
In the control group, positive correlations between the amount of blood flow after weeks 2 and 4 of treatment and WSA decrease between weeks 2 and 4 and 4
and 8 were not noted. More research is necessary to determine the exact role of
wound blood flow changes observed with HVMPC and between anodal and cathodal HVMPC in PU wound healing.
The primary research outcome in this study was percentage change in PSBF after
2 and 4 weeks of treatment. After 2 weeks of applying HVMPC, PSBF increased in
the AG by 109.52% and in the CG by 131.54%. Both rates were significantly higher
than in the PG (35.83%). Between weeks 2 and 4 of treatment, PSBF slightly decreased in all groups studied, but after 4 weeks it was still higher than at baseline by
89.3% in the AG, 88.25% in the CG, and 34.53% in the PG. No clinical studies were
found that compared how anodal and cathodal HVMPC influences PSBF and area
reduction of PUs (or other chronic wounds).
Several clinical studies22-24 on wounds of mixed etiology (including PUs and
diabetic foot ulcers) showed biphasic currents increase PSBF and reduce wound
area, results similar to those obtained in the present study. In these studies,22-24
researchers applied biphasic charge-balanced sine wave current (30 Hz; 250 µs; 20
mA) for 30 minutes once a day, 3 times a week, for 4 weeks. Current was delivered
via electrodes attached to the opposite wound edges. In these 3 studies,22-24 as well
as in the present study, current amplitude was set at sensory level without eliciting
muscle contractions.
In the randomized clinical study by Lawson and Petrofsky,22 ES was applied to 2
groups of 10 patients with Stage 3 and Stage 4 chronic wounds of mixed etiology.
The groups included patients with type 2 diabetes (mean age 64.7 years; mean ulcer
duration 10.6 months) and nondiabetic patients (mean age 55.3 years; mean ulcer
duration 12.7 months). Both groups received ES. After 2 weeks of treatment, PSBF
measured before an ES procedure in patients with diabetes was 35% greater than at
baseline and significantly greater than in nondiabetic patients whose PSBF did not
change over that period (P <.003). At week 4 of treatment, PSBF before ES in patients with diabetes was 21% greater than at baseline and in nondiabetic patients an
increase of 18% was noted (P >.05). PSBF in patients with diabetes measured during
ES was significantly greater than in nondiabetic patients after both 2 and 4 weeks of
treatment. At week 2, the PSBF in patients with diabetes increased by 215%, as opposed to nondiabetic patients’ whose PSBF did not change significantly (P <.003).
PBSF measured at week 4 in patients with diabetes was 87% higher compared with
only 6% in nondiabetic patients (P <.003). Lawson and Petrofsky22 also noted that
the 4-week healing rate for patients with diabetes was 70.0%, while the healing rate
for the other patients was 38.4%, a statistically significant difference (P <.01).
Suh et al23 conducted a pilot study without a control group where 18 persons (10
men, 8 women, mean age 35.7 years) with chronic ulcers of mixed etiology (mainly
Stage 3 and Stage 4 PUs and diabetic ulcers; mean area 10.7 cm2) unhealed after 26.1
months’ duration received ES. Twenty (20) minutes before each ES procedure, the
wound and periwound skin were warmed to 37˚ C using thermal energy from an IR
heat lamp. This temperature was maintained until the ES procedure ended. After 4
weeks of treatment, a mean increase in PSBF recorded 20 minutes after the lamp
was switched on was 9.3% (P >.05); the application of ES resulted in a significant
increase in PSBF by an average of 15.6% (P <.05) after 30 minutes. During the
4 weeks of treatment, wound measurements decreased by 43.4% (P <.05). The
authors also observed that PSBF increased from the beginning and well past the
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found the approximate length of treatment necessary to decrease area in Stage 2 to Stage 4 PUs by 50% was 4.30 weeks in
the AG and 3.86 weeks in the CG — in both scenarios, times
significantly shorter statistically than in the PG (9.86 weeks).
Thus far, no clinical studies have compared the influence
of anodal and cathodal HVMPC or other electrical currents
on the healing of PUs or other types of wounds. However, the
results of the existing clinical research show both anodal and
cathodal HVMPC promote the healing of PUs, which supports present results.10,11,17,18
In the study by Kloth and Feedar,10 anodal stimulation
with HVMPC + SWC (9 patients) decreased the surface area
of Stage 4 PUs by an average of 44.8% a week. Wounds closed
completely over a period of 7.3 weeks. In the control group
(7 patients) that received sham ES + SWC, wound area increased by 28.8% over a mean period of 7.4 weeks.
In Griffin et al,11 HVMPC + SWC decreased the area of 8
Stage 2 to Stage 4 PUs by 80% after 3 weeks of cathodal ES, a
result that was significantly greater than in the control group
(sham ES + SWC; 9 patients), where PUs decreased by an average of 52% (P <.05).
In the study by Polak et al,17 6 weeks of cathodal HVMPC
+ SWC (25 patients) decreased the area of Stage 2 to Stage 3
PUs by 88.31%, also significantly better than in the control
group (sham HVMPC + SWC; 24 patients) where wound
area decreased by an average of 54.65% (P = .046). The Polak et al17 study also showed that in the group treated with
cathodal HVMPC + SWC, 45% of Stage 2 PUs and 17.65%
of Stage 3 PUs closed after 6 weeks of treatment compared
with 35.29% of Stage 2 PUs and 6.25% of Stage 3 PUs in the
control group (sham HVMPC + SWC). The results were not
significantly different between the groups (P = .74 and P =
.60, respectively).
In an additional study by Polak et al,18 the surface area of
23 Stage 2 to Stage 4 PUs decreased after 6 weeks of cathodal
HVMPC + SWC by an average of 82.34%. This result was significantly greater than in the control group (sham HVMPC
+ SWC), where average decrease in WSA was 40.53% (P =
.0006). Cathodal HVMPC was therapeutically as effective as
1 week of anodal stimulation followed by 5 weeks of cathodal stimulation that reduced WSA by 70.77% (P = .9932).
WSA decrease induced by anodal plus cathodal stimulation
also was significantly greater than in the control group (P =
.0124). In the group treated with cathodal HVMPC + SWC,
47.8% of Stage 2 to Stage 4 PUs closed over 6 weeks, compared with 45% of Stage 2 to Stage 4 PUs (P = .48) in the
group receiving anodal plus cathodal HVMPC + SWC. In
both ES groups, the percentage of PUs that closed was significantly greater than in the control group, where not a single
PU closed (P = .013 and P = .045, respectively).
Implications for clinicians and policymakers. In designing the protocol for the application of HVMPC, the authors
referred to solutions used by other authors.10-18 After sterilizing, the treatment electrode was placed on the wound and
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middle of the study (2 weeks) (P <.05) but decreased toward the end of treatment (statistically, the changes were
not significant;P >.05).
In a longitudinal, randomized, clinical study by Petrofsky et al,24 20 patients (mean age 48.4 years) with nonhealing diabetic foot ulcers (mean duration 38.9 months) were
randomly divided into 2 groups. Groups were treated with
local dry heat (heat group; n = 10; mean WSA was 28.2 cm2)
or local dry heat + ES (heat + ES group; n = 10; mean WSA
was 24.1 cm2). In both groups, local heating was provided
by an IR lamp positioned 5 cm above the wound to warm
the wound area to 37˚ C. Before treatment, the average blood
flow was greatest in the center of the wounds. The average
blood flow for all participants in both groups was 112.3 flux
in the outside of the wound, 224.3 flux on the edge of the
wound, and 385.7 flux in the center of the wound. On the
first day of the study, the average blood flow from all 3 areas
increased from baseline by 102.3% in the heat group and by
152.3% in the heat + ES group. By the last day of the study,
the average blood flow in all 3 areas had decreased by 54.5%
in both groups. Blood flow differences between the groups
were not significant, but percentage wound area reduction in
the heat + ES group at week 4 was significantly greater than
in the heat group (68.4% and 30.1%, respectively; P <.05).
The authors of the cited studies22-24 reported blood flow
was greater after weeks 2 and 4 of treatment than at baseline. As in the current study, blood flow was at its highest
at week 2 and then decreased. The authors also stated that
after 4 weeks of treatment with biphasic current surface
area of mixed etiology, wound size decreased from 38.4% to
70%. In the current study, 8 weeks of treatment with anodal
and cathodal HVMPC reduced wound area by 64.10% and
74.06%, respectively.
In the cited studies,22-24 blood flow was measured using
laser Doppler imaging and computerized image analysis. A
study on healthy people by Wikstrom et al40 found both laser Doppler flowmetry and intravital video microscopy to be
useful in studying the microcirculation in the healthy skin
and in the skin around experimental blister wounds. In the
present study, Doppler flowmetry was used; skin temperature
under the probe head was 33˚ C. In the cited studies,22-24 skin
temperature during ES procedures and PSBF measurements
was 37˚ C. In the study by Petrofsky et al38 among healthy
men, biphasic square wave ES (30 Hz; 250 µs; 15 minutes; 15
mA) increased skin blood flow when skin temperature was
maintained at 30˚ C and 40˚ C, but at 20˚ C no significant
change in skin blood flow was observed.
The secondary research outcome in the current study was
the healing rate and percentage decrease in PU surface area,
which also was used by the authors of other clinical studies
evaluating the efficacy of wound treatment.10-18 The percentage reduction in wound area noted at week 8 was significantly greater in the AG and CG than in the PG (64.10% in the
AG, 74.06% in the CG, and 41.42% in the PG). The authors
26
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pare PUs treated with anodal versus cathodal HVMPC. More
clinical research is necessary to determine how the polarity
of the treatment electrode influences wound healing. More
research is also necessary to determine whether anodal or
cathodal HVMPC accelerates wound healing by stimulating blood flow in the wound area. Future clinical trials also
should investigate the influence of electrical currents on the
concentrations of pro- and anti-inflammatory factors such as
cytokines and growth factors in wounds.
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Limitations
This study has several strengths. First, the research team
(physicians, nurses, physiotherapists), the person in charge
of measuring WSA, and the statistician were blinded as to
treatment provided. Second, the participants were hospitalized at the same rehabilitation center, making it possible for
the medical staff to supervise the uniform application of
PU prevention measures and treatments and to ensure the
ES protocol was observed at all times. Third, wound sizes
were measured based on valid and reliable acetate tracings.
Fourth, all patients completed at least 4 weeks of treatment,
so PSBF4 and PAR4 could be calculated and compared for
all of them. Finally, the intent-to-treat analysis employed
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the return electrode on intact periwound skin at least 15 cm
from the wound edge. Both electrodes were separated from
the tissue by sterile gauze pads, which were moistened with
physiological saline to improve electrical conductivity and
maintain a moist wound environment.
Previous and present research showed HVMPC with twinpeaked pulses (50-154 µs, 100 pps) used to treat PUs,10,11,15-18
venous leg ulcers,12,14 and diabetic foot ulcers13 is therapeutically efficient. In the study, 0.36 A and an electric charge of
360 µC/sec (1.08 C/day) in the voltage range from 100 to 150
V was applied; in other studies, the electrical charge ranged
from 250 – 500 µC/sec (0.89 – 1.78 C/day).10,11,17-20,41 Following the protocols used by other researchers,10-18 the amperage
used in the present study could be detected only by cutaneous receptors.
Most authors10-12,14,16-18 applied HVMPC to wounds for 45
minutes to 60 minutes, once a day, 3 to 7 days a week, so
treatment time ranged from 2.25 to 7 hours per week. The
sessions in this study were similar in duration (50 minutes,
5 days/week; total treatment time of 4.16 hours of a week).
The results of preclinical ES reports7,42-44 note the polarity
of the treatment electrode is important in managing chronic
wounds, but this clinical trial appears to be the first to com-
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the exponential regression function, which allows WSA decreases to be precisely represented, to approximate the likely
treatment results between weeks 4 and 8.
However, the study was not without limitations. A major limitation of the study is that the period of treatment
was insufficient for all PUs to close. Consequently, length of
treatment (ie, optimal treatment time of anodal or cathodal
HVMPC to facilitate complete closure of Stage 2 to Stage
4 PUs) could not be determined. The blinding rate of patients and assessors was not assessed. Another limitation
is the relatively high dropout rate between weeks 4 and 8
(31.15%); some patients were discharged from the hospital
to be treated at home and a number of others were moved
to other wards for treatment for concomitant diseases. This
thwarted the monitoring of the healing of their PUs. The PU
prevention and treatment program for all 3 groups generally followed the same best practice recommendations,1,2,37
but its specific solutions addressed the needs of individual
patients. Finally, the sample size in each group was too small
to control for the potential effect of baseline variables such
as ulcer depth/stage and start of treatment wound characteristics on study outcomes.
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Conclusion
This study demonstrated that anodal and cathodal
HVMPC with double-peaked impulses (154 µs; 100 pps;
above 100 V; 360 µC/sec; 1.08 C/day) administered 50 minutes a day, 5 times a week, can be used in clinical practice to
improve PSBF and promote healing of Stage 2 to Stage 4 PUs
in patients with neurological injuries. These results are consistent with those obtained by other researchers who also reported HVMPC can improve the healing of chronic wounds,
including PUs. However, this is the first study to document
that type of ES (anodal or cathodal) did not affect wound
blood flow and wound size reduction in patients with PUs.
Future clinical trials are necessary to elucidate the nature
of the relationship between the stimulation of wound blood
flow following anodal and cathodal HVMPC and change in
wound area. n
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